Haima Therapeutics is a pre-clinical stage biotechnology company developing platelet-inspired technologies for the treatment of hemorrhage, thrombosis, (thrombo)inflammation, and other blood-related pathologies. Haima’s initial focus is on platelet’s primary responsibility, hemostasis, wherein they are developing platelet-inspired therapies to mitigate bleeding in multiple therapeutic indications, including traumatic injury, surgery, and thrombocytopenia. Haima’s lead product is called SynthoPlate, a novel, fully-synthetic hemostatic technology that mitigates bleeding by acting at the site of injury and amplifying your body’s natural clotting mechanisms.